Comparative review of dopamine receptor agonists in Parkinson's disease

CNS Drugs

Volumn 5, Issue 5, 1996, Pages 369-388

  Uitti, Ryan J ^a   Ahlskog, J Eric ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; N,N DIETHYL N' (1 ETHYL 6 METHYL 8ALPHA ERGOLINYL)SULFAMIDE; NAXAGOLIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; QUINAGOLIDE; ROPINIROLE; TALIPEXOLE; TERGURIDE;

DYSKINESIA; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029895570     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605050-00006     Document Type: Review

References (123)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth, 1987: 96-122
2. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989; 39 Suppl. 2: 11-9
3. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979; 277: 93-6
4. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986; 9: 357-81
5. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-32
6. Gerlen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1993; 15: 133-9
7. Kebabian JW. Neurotransmitter receptors in neurodegeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: W.B. Saunders Company, 1994: 119-26
8. 2 dopamine receptors in the expression of dopamine agonist induced behaviors. Ad Exp Med Biol 1986; 204: 151-66
9. 2 dopamine agonists on turning behaviour in rats. Brain Res 1986; 384: 387-90
10. 2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study. Brain Res 1987; 400: 205-18
11. 2 agonist effects. Science 1987; 236: 719-22
12. 2 dopamine receptor mechanisms in dopaminergic behaviors. Clin Neuropharmacol 1988; 11: 221-31
13. 2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 1994; 9: 664-72
14. Rouillard C, Bedard PJ, Di Paolo T. Behavioral and biochemical effect of chronic treatment of MPTP-monkeys with bromocriptine alone or in combination with SKF-38393. Eur J Pharmacol 1990; 185: 209-15
15. 1 agonist CY208-243 to chronic bromocriptine treatment. 1: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Mov Disord 1993; 8: 144-50
16. Gershanik O, Heikkila RE, Duvoisin RC, Behavioral correlations of dopamine receptor activation. Neurology 1983; 33: 1489-92
17. 1 dopamine receptors are stimulated with SKF38393. Psychopharmacology 1986; 90: 147-9
18. 3) as a target for neuroleptics. Nature 1990; 347: 146-51
19. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-4
20. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995; 45 Suppl. 3: S6-12
21. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990; 40 Suppl. 3: 50-4
22. Mena MA, Pardo B, Casarejos JJ, et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992; 7: 23-31
23. Fornstedt B. Role of catechol autooxidation in the degeneration of dopamine neurons. Acta Neurol Scand 1990; 129 Suppl.: 12-4
24. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990; 40 Suppl. 3: 32-7
25. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381-9
26. Shoulson I. Experimental therapeutics directed at the pathogenesis of Parkinson's disease. In: Calne DB, editor. Drugs for the treatment of Parkinson's disease (handbook of experimental pharmacology. Vol. 88). New York: Springer-Verlag, 1988: 289-305
27. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 1989; 86: 1398-400
28. Tsui JKC. Treatment of Parkinson's disease. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: W.B. Saunders Company, 1994: 573-82
29. Lieberman A, Bromocriptine in Parkinson's disease. In: Koller WC, Paulson G, editors. Therapy of Parkinson's disease. New York: Marcel Dekker Inc., 1990: 255-67
30. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993; 46: 384-93
31. The Parkinson Study Group. Effect ot deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
32. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-83
33. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985; 35: 1196-8
34. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826-8
35. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993; 8: 257-62
36. Weiner WJ, Lang AE, editors. Parkinson's disease. Movement disorders: a comprehensive survey. Mount Kisco, NY: Futura Publishing Company, 1989: 23-115
37. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989; 52: 773-5
38. Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 1004-7
39. 2 (pergolide). Arch Neurol 1992; 49: 560-8
40. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990; 40: 927-33
41. Jenner P. Parkinson's disease: pathological mechanisms and action of piribedil. J Neurol 1992; 239 Suppl. 1: S2-8
42. Fuller RW, Clemens JA, Hynes III MD. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesias. J Clin Psychopharmacol 1982; 2: 371-5
43. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 1992; 13: 339-51
44. Parkes JD, Schachter M, Marsden CD, et al. Lisuride in parkinsonism. Ann Neurol 1981; 9: 48-52
45. Lieberman A, Goldstein M, Neophytides A, et al. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa. Neurology 1981; 31: 961-5
46. Montastruc JL, Llau ME, Rascol O, et al. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994; 8: 293-306
47. Coleman RJ, Lange KW, Quinn NP, et al. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Mov Disord 1989; 4: 129-38
48. Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet 1986; 1: 467-70
49. Schran HF, Bhuta SI, Schwarz HJ, et al. The pharmacokinetics of bromocriptine in man. Adv Biochem Psychopharm 1980; 23: 125-39
50. Humpel M, Nieuweboer B, Hasan SH, et al. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effects on plasma prolactin level. Eur J Clin Pharmacol 1981; 20: 47-51
51. Koller WC, Weiner WJ, Diamond SG, et al. The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent. Neuropharmacol 1980; 19: 831-7
52. Ahlskog JE, Wright KF, Muenter MD. et al. Adjunctive cabergoline therapy of Parkinson's disease: response duration and dose responses. Clin Neuropharmacol. In press
53. Mannen T, Mizuno Y, Iwata M, et al. A multi-center, double-blind study on slow-release bromocriptine in the treatment of Parkinson's disease. Neurology 1991; 41: 1598-602
54. LeWitt PA, Ward C-D, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1009-14
55. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9: 431-6
56. Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995; 45 Suppl. 3: S22-7
57. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45: S13-21
58. Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 1983; 37: 95-108
59. Goetz CG, Tanner CM, Glantz RH, et al. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35: 749-51
60. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988; 51: 529-33
61. Olanow CW. Pergolide/Parlodel crossover study [abstract]. Neurology 1988; 38: 314
62. Goetz CG, Shannon KM, Tanner CM, et al. Agonist substitution in advanced Parkinson's disease. Neurology 1989; 39: 1121-2
63. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993; 60: 653-5
64. Inzzelberg R, Nisipeanu P, Rabey JM, et al. Comparison of cabergoline (CBG) and bromocriptine (BCR) in Parkinson's disease (PD) patients with motor fluctuations [abstract]. Neurology 1995; 45: A292
65. Ferrari C, Barbieri C, Caldara R, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941-5
66. Ferrari C, Paracchi A, Romano C, et al. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol 1988; 29: 467-76
67. European Multicentre Study Group for Canergoline in Lactation and Inhibition. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double-blind, multicentre study. BMJ 1991; 302: 1367-71
68. LeWitt PA, Gopinathan G, Ward CD, et al. Lisuride versus bromocriptine treatment in Parkinson disease: a double blind study. Neurology 1982; 32: 69-72
69. Lees A J, Stern GM. Pergolide and lisuride for levodopa-induced oscillations [letter]. Lancet 1981; I: 577
70. Lieberman AN, Gopinathan G, Neophytides A, et al. Pergolide and lisuride in advanced Parkinson's disease. In: Hassler RG. Christ JF, editors. Parkinson-specific motor and mental disorders, role of pallidum: pathophysiological, biochemical, and therapeutic aspects. New York: Raven Press, 1984: 503-7
71. Pacchetti C, Martignoni E, Bruggi P, et al. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. Mov Disord 1993; 8: 463-5
72. Cotzias GC, Papavasiliou PS, Tolosa ES, et al. Treatment of Parkinson's disease with aporphines. N Engl J Med 1976; 294: 576-72
73. Horowski R, Obeso JA. Lisuride: a direct dopamine agonist in the treatment of Parkinson's disease. In: Koller WC, Paulson E, editors. Therapy of Parkinson's disease. New York: Marcel Dekker Inc., 1990: 269-309
74. Dewey RB, Maraganore DM, Ahlskog JE, et al. Intranasal apomorphine rescue therapy for parkinsonian 'off' periods. Clin Neuropharmacol. In press
75. Vermersch P, Petit H. Long-term selegiline tolerance in the treatment of Parkinson's disease. Therapie 1992; 47: 75-8
76. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease [letter]. Lancet 1981; II: 44
77. Wiggins J, Skinner C. Bromocriptine induced pleuropulmonary fibrosis. Thorax 1986; 41: 328-30
78. McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Int Med 1988; 148: 2231-6
79. Demonet JF, Rostin M, Dueymes JM, et al. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol 1986; 9: 200-1
80. Bhatt MH, Keenan SP, Fleetham JA, et al. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991; 30: 613-6
81. LeWitt PA, Calne DB. Recent advances in the treatment of Parkinson's disease: the role of bromocriptine. J Neural Transm 1981; 51: 175-84
82. Tornling G, Unge G, Axelsson G, et al. Pleuropulmonary reactions in patients on bromocriptine treatment. Eur J Respir Disord 1986; 68: 35-8
83. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992; 5: 263-5
84. Graham JR, Suby HI, LeCompte PR, et al. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966; 274: 359-68
85. Cotzias CG, Mena I, Papavasiliou PS, et al. Unexpected findings with apomorphine and their consequences. Adv Neurol 1974; 5: 295-9
86. Calne DB, Teychenne PF, Claveria LR, et al. Bromocriptine in parkinsonism. BMJ 1974; 4: 442-4
87. Lieberman AN, Goldstein M. Bromocriptine in Parkinson's disease. Pharmacol Rev 1985; 37: 217-27
88. Lieberman AN, Kupersmith M, Estey E, et al. Treatment of Parkinson's disease with bromocriptine. N Engl J Med 1976; 295: 1400-3
89. Vance ML, Evans WS, Thorner MO. Diagnosis and treatment five years later: bromocriptine. Ann Int Med 1984; 100: 78-89
90. Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990; 47: 694-7
91. Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, et al. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986; 36: 291-3
92. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994; 62: 1034-8
93. Ahlskog JE, Muenter MD. Treatment of Parkinson's disease with pergolide: a double-blind study. Mayo Clin Proc 1988; 63: 969-78
94. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985; 35: 291-5
95. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9: 40-7
96. Vaamonde J, Luquin MR, Obeso JA. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. Mov Disord 1990; 5: 260-2
97. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992; 32: 776-81
98. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study. J Neurol 1992; 239 Suppl. 1: S28-34
99. Gancher ST, Woodward WR, Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232-8
100. Frankel JP, Lees AJ, Kempster PA. et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96-101
101. Kleedorfer B, Turjanski N, Ryan R, et al. Intranasal apomorphine in Parkinson's disease. Neurology 1991; 41: 761-2
102. Van Laar T, Jansen ENH, Essink AWG, et al. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992; 49: 482-4
103. Stibe CMH, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 1: 403-6
104. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-70
105. Jori MC, Franceschi M, Giusti MC, et al. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. Adv Neurol 1990; 53: 539-43
106. Benedetti MS, Dostert P, Barone D, et al. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990; 187: 399-408
107. Fariello RG, Carfagna N, Buonamici M, et al. Cabergoline: a long-acting D2 agonist with antiparkinsonian properties - preclinical studies [abstract]. Ann Neurol 1991; 30: 258
108. Ahlskog JH, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994; 51: 1236-41
109. Hutton JT, Morris JL, Brewer MA. Controlled study of the anti-parkinsonian activity and tolerability of cabergoline. Neurology 1993; 43: 613-6
110. Leiberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993; 43: 1981-4
111. Hutton JT, Hurtig H, Hiner B, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease [abstract]. Neurology 1995; 45 Suppl. 4: A203
112. Lera G, Vaamonde J, Muruzabal J, et al. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990; 28: 593-4
113. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993; 43: 2587-90
114. Baronti F, Ruggieri S, Stocchi F, et al. Terguride therapy of Parkinson's disease [abstract]. Mov Disord 1992; 7: 98
115. 2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991; 200: 65-72
116. 3 receptors. Eur J Pharmacol 1994; 263: 235-43
117. Albani C, Popescu R, Lacher R, et al. Single dose response to pramipexole in patients with Parkinson's disease [abstract]. Mov Disord 1992; 7: 98
118. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine agonist, in advanced Parkinson's disease. Neurology 1993; 43: A384-5
119. Irifune M, Nomoto M, Fukuda T. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment. Eur J Pharmacol 1994; 264: 117-23
120. 2 agonist. Pharmacol Biochem Behav 1991; 38: 147-54
121. Pfeiffer RF, Hofman R. CQA 206-291 in Parkinson's disease. Clin Neuropharmacol 1991; 14: 170-8
122. Rascol O, Fabre N, Teravainen H, et al. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. Clin Neuropharmacol 1990; 13: 303-11
123. Olanow CW, Werner EG, Gauger LL. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study. Clin Neuropharmacol 1989; 12: 490-7